Osteoarthritis of the Knee Clinical Trial
Official title:
A Multi-Center, Randomized, Double-Blind, Controlled, Parallel-Group Study of a Single Intra-Articular Injection of Gel-200 With a Single Intra-Articular Injection of Phosphate Buffered Saline (PBS) in Osteoarthritis of the Knee.
Verified date | October 2011 |
Source | Seikagaku Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine if a single intra-articular injection of Gel-200 is superior to a single injection of Phosphate Buffered Saline (PBS) in subjects with symptomatic osteoarthritis of the knee.
Status | Completed |
Enrollment | 379 |
Est. completion date | December 2007 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Subjects with a diagnosis of painful, symptomatic tibio-femoral osteoarthritis of the knee (Grade 1-3 on Kellgren - Lawrence (K-L) score). Exclusion Criteria: - Subjects with Grade 4 on K-L score - Subjects with inflammatory diseases of the knee other than osteoarthritis such as rheumatoid arthritis - Serious systemic diseases - Female subjects who are pregnant or lactating |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | SKK | Plantation | Florida |
Lead Sponsor | Collaborator |
---|---|
Seikagaku Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Visual Analog Scale (VAS) Pain Subscore | Observed WOMAC pain subscore on VAS of 100 mm; 0 mm meaning no pain; 100 mm meaning extreme pain. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo. | Baseline and Week 13 | No |
Secondary | Change From Baseline in WOMAC VAS Stiffness Subscore | Observed WOMAC stiffness subscore on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no stiffness; 100 mm meaning extreme stiffness. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo. | Baseline and Week 13 | No |
Secondary | Change From Baseline in WOMAC VAS Physical Function Subscore | Observed WOMAC physical function subscore on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no difficulty; 100 mm meaning extreme difficulty. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo. | Baseline and Week 13 | No |
Secondary | Change From Baseline in WOMAC VAS Total Score | Mean of all WOMAC pain, stiffness and physical function subscores on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no pain, stiffness and difficulty; 100 mm meaning extreme pain, stiffness and difficulty. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo. | Baseline and Week 13 | No |
Secondary | Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT)- and the Osteoarthritis Research Society International (OARSI) Response | Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) strict responses defined by changes from baseline in WOMAC pain or physical function subscore =50% with absolute changes =20 mm (termed strict responders), or =20% with absolute changes =10mm in 2 of 3 measures of WOMAC pain or physical function subscore or subject global evaluations (termed responders). | Weeks 6 to 13 | No |
Secondary | Change From Baseline in Short Form - 36 (SF-36) | Scored on physical component scale from 0 (negative health) to 100 (positive health). Calculated norm based with a mean of 50 and a standard deviation of 10. | Baseline and Week 13 | No |
Secondary | Change From Baseline in Subject Global Evaluations | Observed subject evaluations on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning excellent feeling in knee joint; 100 mm meaning poor feeling in knee joint. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo. | Baseline and Week 13 | No |
Secondary | Change From Baseline in Physician Global Evaluations | Observed physician global evaluations on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning excellent feeling in knee joint; 100 mm meaning poor feeling in knee joint. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo. | Baseline and Week 13 | No |
Secondary | Acetaminophen Consumption | Weekly mean acetaminophen consumption between weeks 9 and 13. | Weeks 9 to 13 (5 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03277066 -
A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis
|
Phase 2 | |
Recruiting |
NCT03090698 -
Outcomes of Injections in Patients Waiting for Total Knee Replacement
|
Phase 4 | |
Completed |
NCT02556710 -
A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee
|
Phase 3 | |
Withdrawn |
NCT02237846 -
Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis
|
Phase 1/Phase 2 | |
Completed |
NCT02242435 -
A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis
|
Phase 3 | |
Completed |
NCT01849445 -
Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study
|
N/A | |
Completed |
NCT02096393 -
Patient Specific Instrumentation in TKR
|
N/A | |
Completed |
NCT01704157 -
A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device
|
N/A | |
Active, not recruiting |
NCT01374230 -
Long-Term Multicenter Evaluation of the E1® Tibial Bearing
|
N/A | |
Completed |
NCT01410409 -
Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement
|
N/A | |
Not yet recruiting |
NCT01270412 -
Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis
|
Phase 2/Phase 3 | |
Completed |
NCT02156440 -
Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee
|
Phase 2 | |
Completed |
NCT01207115 -
A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee
|
Phase 2 | |
Completed |
NCT01331278 -
A Comparative Study of Knee Systems
|
Phase 4 | |
Completed |
NCT00988091 -
Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee
|
Phase 3 | |
Completed |
NCT00970008 -
Exploring Massage Benefits for Arthritis of the Knee
|
Phase 2 | |
Completed |
NCT00792727 -
HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain
|
Phase 3 | |
Completed |
NCT00531427 -
Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
|
Phase 3 | |
Completed |
NCT04145011 -
Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain
|
N/A | |
Completed |
NCT01430559 -
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
|
N/A |